Efficiency and safety of subconjunctival injection of anti-VEGF agent – bevacizumab – in treating dry eye

• Main Authors: Jiang X (Author), Lv H (Author), Qiu W (Author), Liu Z (Author), Li X (Author), Wang W (Author)
• Format: Book
• Published: Dove Medical Press, 2015-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Xiaodan Jiang,* Huibin Lv,* Weiqiang Qiu, Ziyuan Liu, Xuemin Li, Wei Wang Department of Ophthalmology, Peking University Third Hospital, Beijing, People&rsquo;s Republic of China *These authors contributed equally as&nbsp;first authors Purpose: Dry eye is a chronic inflammatory ocular surface disease with high prevalence. The current therapies for dry eye remain to be unspecific and notcomprehensive. This study aims to explore safety and efficacy of a novel treatment &ndash; subconjunctival injection of bevacizumab&nbsp;&ndash; in dry eye patients.Methods: Sixty-four eyes of 32 dry eye patients received subconjunctival injection of 100&nbsp;&mu;L 25&nbsp;mg/mL bevacizumab. Dry eye symptoms, signs (corrected visual acuity, intraocular pressure, conjunctival vascularity, corneal staining, tear break-up time, Marx line score, and blood pressure), and conjunctival impression cytology were evaluated 3&nbsp;days before and 1&nbsp;week, 1&nbsp;month, and 3&nbsp;months after injection.Results: Significant improvements were observed in dry eye symptoms, tear break-up time, and conjunctival vascularization area at all the visits after injection compared to the baseline (P<0.05). The density of the goblet cell increased significantly at 1&nbsp;month and 3&nbsp;months after injection (P<0.05). There was no visual and systemic threat observed in any patient.Conclusion: Subconjunctival injection of 100&nbsp;&micro;L 25&nbsp;mg/mL bevacizumab is a safe and efficient treatment for ocular surface inflammation of dry eye disease. Keywords: anti-VEGF, bevacizumab, dry eye, ocular surface inflammation, subconjunctival

Item Description

1177-8881